Baseline thrombocytopenia in acute coronary syndrome: The lower, the worse

Patients with baseline thrombocytopenia can have increased mortality and morbidity, but are typically excluded from randomized clinical trials studying acute coronary syndromes (ACS). We sought to better define the effect thrombocytopenia on clinical outcomes in ACS patients. Patients identified fro...

Full description

Saved in:
Bibliographic Details
Published in:International journal of cardiology 2021-06, Vol.332, p.1-7
Main Authors: Chao, Chieh-Ju, Shanbhag, Anusha, Chiang, Chia-Chun, Girardo, Marlene E., Seri, Amith R., Khalid, Muhammad U., Rayfield, Corbin, O'Shea, Michael P., Fatunde, Olubadewa, Fortuin, F. David
Format: Article
Language:English
Subjects:
Acute coronary syndrome
Antiplatelet therapy
Bleeding
Mortality
Thrombocytopenia
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Patients with baseline thrombocytopenia can have increased mortality and morbidity, but are typically excluded from randomized clinical trials studying acute coronary syndromes (ACS). We sought to better define the effect thrombocytopenia on clinical outcomes in ACS patients. Patients identified from the NCDR Chest Pain registry at Mayo Clinic Arizona from Oct 2015 to Sep 2018 were retrospectively classified into two groups: TP (platelet
ISSN:0167-5273
1874-1754
DOI:10.1016/j.ijcard.2021.03.059